vlog

Skip to content
NOWCAST vlog News at 10pm Sunday Night
Watch on Demand
Advertisement

Pfizer says it's time for a COVID-19 booster. The FDA and CDC say not so fast

Pfizer says it's time for a COVID-19 booster. The FDA and CDC say not so fast
America's covid 19 crisis isn't over infection rates rising in almost half the states, driven in part by the more contagious delta variant, low vaccination rates, putting the country's progress fighting the virus at risk. The more unvaccinated people their arm, the longer this pandemic is going to be. This is not just about the individual, this is about our society at Georgetown University analysis showing five clusters of counties with low vaccination rates and significant population sizes stretching from Georgia to texas to Missouri. Places that could become breeding grounds for more deadly covid variants. A stronger mutation will surface and it will become predominant unless we get vaccinated New cases jumping more than 50% week over week in Louisiana were just 35% are fully vaccinated And Tennessee where it's about 38% simply put in areas of low vaccination coverage. Hospitalizations are up with less than half the population fully vaccinated nationwide. The White House ramping up outreach to pediatricians at workplaces and on school campuses. Our job is to keep doing all we can to reach americans where they are to answer their questions and to make it as easy as possible for them to get a shot. As soon as they are ready. And efforts to have doctors and religious and community leaders going door to door to answer questions for the vaccine, hesitant for those individuals organizations that are feeding misinformation and trying to mischaracterize this type of trusted messenger work. I believe you are doing a disservice to the country and to the doctors, the faith leaders, community leaders and others who are working to get people vaccinated, save lives and help end this pandemic data show the Pfizer Moderna and johnson and johnson vaccines are effective including against the delta variant, which now accounts for more than half of all new cases. Please get vaccinated. It will protect you against the surging of the delta variant in Maryland. Every person who died of covid in june was unvaccinated and as entertainers like the rapper juvenile try to appeal to young people, experts are hoping full approval for vaccines from the U. S. Food and Drug Administration will encourage more people to get the shot right now. The shots only have emergency use authorization. Meanwhile, mask mandates are back in California state capitol after an outbreak of covid cases among employees as covid fears ramp up all over again.
Advertisement
Pfizer says it's time for a COVID-19 booster. The FDA and CDC say not so fast
Drugmaker Pfizer said Thursday it is seeing waning immunity from its coronavirus vaccine and is picking up its efforts to develop a booster dose that will protect people from variants.Pfizer said it would soon publish data about a third dose of vaccine and submit it to the U.S. Food and Drug Administration, European Medicines Agency and other regulators. The company specified it would seek FDA emergency use authorization for a booster dose in August.But in an unusual move, two top federal agencies said Americans don't need boosters yet and said it was not up to companies alone to decide when they might be needed.Hours after Pfizer issued its statement, the FDA and Centers for Disease and Control and Prevention issued a joint statement saying Americans do not need booster shots yet."Americans who have been fully vaccinated do not need a booster shot at this time," they said.In a statement to CNN on Friday, the World Health Organization said, "We don't know whether booster vaccines will be needed to maintain protection against COVID-19 until additional data is collected," adding, "limited data available on how long the protection from current doses lasts and whether an additional booster dose would be beneficial and for whom."Pfizer and its partner BioNTech said evidence was building that people's immunity starts to wane after they have been vaccinated. The Pfizer vaccine requires two doses to provide full immunity."As seen in real world data released from the Israel Ministry of Health, vaccine efficacy in preventing both infection and symptomatic disease has declined six months post-vaccination, although efficacy in preventing serious illnesses remains high," Pfizer said in a statement emailed to CNN."Additionally, during this period the Delta variant is becoming the dominant variant in Israel as well as many other countries. These findings are consistent with an ongoing analysis from the Companies' Phase 3 study," it added."While protection against severe disease remained high across the full six months, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected. Based on the totality of the data they have to date, Pfizer and BioNTech believe that a third dose may be beneficial within 6 to 12 months following the second dose to maintain highest levels of protection." It gave no further details.The announcement could have implications across the world. The Pfizer shot is the cornerstone of vaccination programs in many countries. Two-thirds of doses delivered across the European Union were made by Pfizer, according to the European Center. In Israel, Pfizer is the only vaccine used.Of the 158 million fully vaccinated people in the U.S., more than half received the Pfizer shot.U.S. government officials have stressed that fully vaccinated people have a low risk of infection, even from the delta variant, which is more transmissible than earlier lineages of the virus.Plus, several studies have indicated the mRNA vaccines made by Pfizer and Moderna confer long-term protection."FDA, CDC, and NIH (the National Institutes of Health) are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively," they added.It was a clear message to Pfizer, which has been hinting at the need for a booster shot for months."We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed," the CDC and FDA said in the statement."The United States is fortunate to have highly effective vaccines that are widely available for those aged 12 and up. People who are fully vaccinated are protected from severe disease and death, including from the variants currently circulating in the country such as Delta," the statement continued."People who are not vaccinated remain at risk. Virtually all COVID-19 hospitalizations and deaths are among those who are unvaccinated. We encourage Americans who have not yet been vaccinated to get vaccinated as soon as possible to protect themselves and their community."Israel's health ministry said in a statement earlier this week that it had seen efficacy of Pfizer's vaccine drop from more than 90% to about 64% as the delta variant spread.Pfizer said research showed booster doses of its vaccine, developed with BioNTech, produced levels of neutralizing antibodies that are five to 10 times higher than what's produced after two doses.It said it's also developing a new formulation for a booster dose that may more thoroughly protect people from new variants."While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant," the company said. Current vaccines target just a piece of the spike protein — the part of the virus it uses to attach to cells."The first batch of the mRNA for the trial has already been manufactured at BioNTech's facility in Mainz, Germany. The Companies anticipate the clinical studies to begin in August, subject to regulatory approvals."

Drugmaker Pfizer said Thursday it is seeing waning immunity from its coronavirus vaccine and is picking up its efforts to develop a booster dose that will protect people from variants.

Pfizer said it would soon publish data about a third dose of vaccine and submit it to the U.S. Food and Drug Administration, European Medicines Agency and other regulators. The company specified it would seek FDA emergency use authorization for a booster dose in August.

Advertisement

But in an unusual move, two top federal agencies said Americans don't need boosters yet and said it was not up to companies alone to decide when they might be needed.

Hours after Pfizer issued its statement, the FDA and Centers for Disease and Control and Prevention issued a joint statement saying Americans do not need booster shots yet.

"Americans who have been fully vaccinated do not need a booster shot at this time," they said.

In a statement to CNN on Friday, the World Health Organization said, "We don't know whether booster vaccines will be needed to maintain protection against COVID-19 until additional data is collected," adding, "limited data available on how long the protection from current doses lasts and whether an additional booster dose would be beneficial and for whom."

Pfizer and its partner BioNTech said evidence was building that people's immunity starts to wane after they have been vaccinated. The Pfizer vaccine requires two doses to provide full immunity.

"As seen in real world data released from the Israel Ministry of Health, vaccine efficacy in preventing both infection and symptomatic disease has declined six months post-vaccination, although efficacy in preventing serious illnesses remains high," Pfizer said in a statement emailed to CNN.

"Additionally, during this period the Delta variant is becoming the dominant variant in Israel as well as many other countries. These findings are consistent with an ongoing analysis from the Companies' Phase 3 study," it added.

"While protection against severe disease remained high across the full six months, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected. Based on the totality of the data they have to date, Pfizer and BioNTech believe that a third dose may be beneficial within 6 to 12 months following the second dose to maintain highest levels of protection." It gave no further details.

The announcement could have implications across the world. The Pfizer shot is the cornerstone of vaccination programs in many countries. Two-thirds of doses delivered across the European Union were made by Pfizer, according to the European Center. In Israel, Pfizer is the only vaccine used.

Of the 158 million fully vaccinated people in the U.S., more than half received the Pfizer shot.

U.S. government officials have stressed that fully vaccinated people have a low risk of infection, even from the delta variant, which is more transmissible than earlier lineages of the virus.

Plus, several studies have indicated the mRNA vaccines made by Pfizer and Moderna confer long-term protection.

"FDA, CDC, and NIH (the National Institutes of Health) are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data -- which can include data from specific pharmaceutical companies, but does not rely on those data exclusively," they added.

It was a clear message to Pfizer, which has been hinting at the need for a booster shot for months.

"We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed," the CDC and FDA said in the statement.

"The United States is fortunate to have highly effective vaccines that are widely available for those aged 12 and up. People who are fully vaccinated are protected from severe disease and death, including from the variants currently circulating in the country such as Delta," the statement continued.

"People who are not vaccinated remain at risk. Virtually all COVID-19 hospitalizations and deaths are among those who are unvaccinated. We encourage Americans who have not yet been vaccinated to get vaccinated as soon as possible to protect themselves and their community."

Israel's health ministry said in a statement earlier this week that it had seen efficacy of Pfizer's vaccine drop from more than 90% to about 64% as the delta variant spread.

Pfizer said research showed booster doses of its vaccine, developed with BioNTech, produced levels of neutralizing antibodies that are five to 10 times higher than what's produced after two doses.

It said it's also developing a new formulation for a booster dose that may more thoroughly protect people from new variants.

"While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant," the company said. Current vaccines target just a piece of the spike protein — the part of the virus it uses to attach to cells.

"The first batch of the mRNA for the trial has already been manufactured at BioNTech's facility in Mainz, Germany. The Companies anticipate the clinical studies to begin in August, subject to regulatory approvals."